BioSpace News Archive

Senseonics Holdings, Inc. announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.

Cue Biopharma, Inc. announced it will give a poster presentation at the American Society of Clinical Oncology Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.

Kinnate Biopharma Inc. announced the presentation of the design and rationale of a Phase 1 trial-in-progress evaluating the Company’s pan-FGFR inhibitor product candidate, KIN-3248.

IO Biotech (Nasdaq: IOBT), announced today two poster presentations highlighting clinical trials in progress with IO102-IO103 as an investigational agent in combination with pembrolizumab in metastatic solid tumors and in untreated, unresectable or metastatic melanoma at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022.

ImmunoGen, Inc. (Nasdaq: IMGN), today announced additional efficacy data from the pivotal SORAYA study evaluating mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin®.

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it will present interim data from its ongoing Phase 1/2 dose escalation and expansion trial of zotatifin in multiple solid tumors in an oral poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced multiple presentations at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.

Caris Life Sciences® announced that the company and partners within its Precision Oncology Alliance™ will collectively present 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7, 2022.

Regulatory News: Ipsen announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor, Cabometyx®, across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting to be held on 3-7 June.

Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs).